Parkman Healthcare Partners LLC Takes $8.05 Million Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Parkman Healthcare Partners LLC bought a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 72,256 shares of the specialty pharmaceutical company’s stock, valued at approximately $8,050,000. Parkman Healthcare Partners LLC owned 0.12% of Jazz Pharmaceuticals as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. Itau Unibanco Holding S.A. acquired a new position in Jazz Pharmaceuticals in the second quarter valued at about $29,000. EverSource Wealth Advisors LLC boosted its position in shares of Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 97 shares during the period. GAMMA Investing LLC increased its holdings in Jazz Pharmaceuticals by 65.5% in the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 116 shares during the last quarter. Gladius Capital Management LP purchased a new stake in Jazz Pharmaceuticals in the second quarter valued at approximately $33,000. Finally, Venturi Wealth Management LLC boosted its position in shares of Jazz Pharmaceuticals by 577.0% during the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after buying an additional 704 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Royal Bank of Canada increased their target price on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 23rd. TD Cowen dropped their price objective on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Robert W. Baird raised their price target on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research report on Monday, November 18th. JPMorgan Chase & Co. upped their price objective on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a research report on Monday, August 19th. Finally, HC Wainwright reissued a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Three analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $175.33.

Jazz Pharmaceuticals Price Performance

JAZZ stock opened at $121.64 on Wednesday. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The company has a market capitalization of $7.35 billion, a P/E ratio of 17.13, a PEG ratio of 1.03 and a beta of 0.57. The business has a 50 day simple moving average of $115.38 and a 200-day simple moving average of $111.29. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $134.17.

Insider Activity at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the transaction, the executive vice president now directly owns 33,048 shares of the company’s stock, valued at $4,078,453.68. This represents a 10.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the transaction, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. This trade represents a 8.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,110 shares of company stock worth $720,160 in the last 90 days. 4.20% of the stock is owned by insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.